NCT02568384CompletedNot Applicable
Open Label, Single-center Study of the Onyx Meter and App System for Blood Glucose Monitoring in Insulin-Dependent and Insulin-using, Non-Insulin-Dependent Diabetes Mellitus Patients to Demonstrate Usability in a Clinical Setting.
Ascensia Diabetes Care1 site in 1 country45 target enrollmentStarted: October 1, 2015Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 45
- Locations
- 1
- Primary Endpoint
- Percent of Responses From Persons Who Performed Each "Software Operations" Task and Rated Each Statement as Strongly Agree, Agree, or Neither Agree Nor Disagree.
Study Overview
Brief Summary
The purpose of this study is to assess the usability of the Onyx system in the hands of subjects with Insulin Dependent Diabetes Mellitus (IDDM) or insulin-using subjects with Non-IDDM.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Be aged 18-75 years, male or female
- •Read and understand English
- •Have diagnosis of type 1 or insulin-using type 2 diabetes for at least 6 months
- •Be taking multiple daily injections (MDI) of at least two pre-meal bolus injections daily or using an insulin pump
- •Performing self-monitoring of blood glucose at home at least twice daily
- •Have an iOS mobile device or Android mobile device with blue tooth capability
- •iOS device: iPod or iPhone 5 or later version with iOS 8.0 software or higher (no tablets)
- •Android: smart phone, 4.4 version and higher (no tablets)
- •Be willing to utilize the ONYX App on personal mobile device which communicates to meter to manage diabetes (including use of the bolus calculator)
- •Be ambulatory and have transportation to the study site
Exclusion Criteria
- •Hemophilia or any other bleeding disorder
- •Pregnancy
- •Physical, visual or neurological impairments that would make the person unable to perform testing with the BGM
- •Working for a competitive medical device company, or having an immediate family member or someone who is not a family member but is living within the household of someone who works for such a company.
- •A condition, which in the opinion of the investigator or designee, would put the person or study conduct at risk (reason for exclusion will be clearly documented by investigator or designee on the subject disposition form).
- •Proliferative retinopathy or history of retinal laser surgery
Arms & Interventions
Users of Onyx BG Meter / App System
Experimental
Subjects with diabetes used the Onyx Blood Glucose (BG) Meter / App System at home. The enrollment goal for the intended use population:
- 40 to 70% of subjects will have type 1 diabetes
- Not more than 30% of subjects will use an insulin pump
Intervention: Onyx BG Meter / App System (Device)
Outcomes
Primary Outcomes
Percent of Responses From Persons Who Performed Each "Software Operations" Task and Rated Each Statement as Strongly Agree, Agree, or Neither Agree Nor Disagree.
Time Frame: 3 weeks
For "software operations" tasks, subjects rated statements about software operations tasks as 1Strongly Agree, 2Agree, 3Neither Agree nor Disagree, 4Disagree, 5Strongly Disagree, or 6No opinion. Software operations tasks included: * Obtain a synced blood glucose reading * Initiation and use of insulin bolus calculator * Access and interpret glucose displays such as expanded graph (modal day) and sequential views.
Secondary Outcomes
- Percent of Responses From Persons With Diabetes That Rated Ease of Use For Onyx Glucose Meter and App System as Either Very Simple or Simple or Neither Simple Nor Difficult(3 weeks)
- Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Clarity and Utility of User Instructions For Onyx Glucose Meter and App System(3 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk PatientsCoronary Artery DiseaseNCT03344653Medtronic Vascular2,000
Terminated
Not Applicable
Safety and Performance Study of the Nyxoah SAT System for Treating OSAObstructive Sleep ApneaNCT02312479Nyxoah S.A.6
Completed
Not Applicable
A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)Coronary Artery DiseaseNCT03647475Medtronic Vascular752
Completed
Not Applicable
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 DiabetesType 2 Diabetes MellitusType 1 Diabetes MellitusNCT00229658AstraZeneca1,297
Completed
Phase 2
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral AripiprazoleNervous System DiseasesMental DisorderSchizophreniaNCT02219009Otsuka Pharmaceutical Development & Commercialization, Inc.67